These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20856107)

  • 1. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.
    Mandalos A; Tsakpinis D; Karayannopoulou G; Tsinopoulos I; Karkavelas G; Chalvatzis N; Dimitrakos S
    Cornea; 2010 Dec; 29(12):1373-9. PubMed ID: 20856107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.
    Galor A; Yoo SH; Piccoli FV; Schmitt AJ; Chang V; Perez VL
    Am J Ophthalmol; 2010 Jun; 149(6):926-931.e2. PubMed ID: 20417925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.
    Mauro J; Foster CS
    Semin Ophthalmol; 2009; 24(3):130-4. PubMed ID: 19437347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple subconjunctival bevacizumab for advanced primary pterygium.
    Saxena S; Vishwkarma K; Khattri M; Kishore P
    Ann Ophthalmol (Skokie); 2010; 42 Spec No():28-30. PubMed ID: 21138148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subconjunctival bevacizumab injection in treatment of pterygium.
    Besharati MR; Manaviat MR; Souzani A
    Acta Med Iran; 2011; 49(3):179-83. PubMed ID: 21681707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of subconjunctival bevacizumab on primary pterygium.
    Teng CC; Patel NN; Jacobson L
    Cornea; 2009 May; 28(4):468-70. PubMed ID: 19411971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study.
    Kahook MY
    Am J Ophthalmol; 2010 Sep; 150(3):399-403.e1. PubMed ID: 20570237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study.
    Lekhanont K; Patarakittam T; Thongphiew P; Suwan-apichon O; Hanutsaha P
    Cornea; 2012 Feb; 31(2):155-61. PubMed ID: 22081150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab and stroke.
    Ueta T; Yanagi Y; Tamaki Y; Yamaguchi T
    Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
    [No Abstract]   [Full Text] [Related]  

  • 17. Vascular changes after intra-bleb injection of bevacizumab.
    Coote MA; Ruddle JB; Qin Q; Crowston JG
    J Glaucoma; 2008; 17(7):517-8. PubMed ID: 18854726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
    Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.
    Wu PC; Kuo HK; Tai MH; Shin SJ
    Cornea; 2009 Jan; 28(1):103-4. PubMed ID: 19092418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intralesional bevacizumab injection in decreasing pterygium size.
    Fallah Tafti MR; Khosravifard K; Mohammadpour M; Hashemian MN; Kiarudi MY
    Cornea; 2011 Feb; 30(2):127-9. PubMed ID: 20885313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.